Welcome to our dedicated page for Schrodinger news (Ticker: SDGR), a resource for investors and traders seeking the latest updates and insights on Schrodinger stock.
Schrödinger, Inc. (Nasdaq: SDGR) is a computational science company focused on transforming molecular discovery for drug development and materials design. Its news flow reflects activity across software, collaborations, financial performance and a growing therapeutics portfolio, giving investors and industry observers insight into how its physics+AI platform is being applied in practice.
Recent press releases highlight progress in advancing Schrödinger’s physics+AI computational platform, including a predictive toxicology initiative, an AI-powered conversational interface in its Maestro graphical environment, and integration of Lilly’s TuneLab platform into LiveDesign, its cloud-native enterprise informatics environment. These updates illustrate how the company combines physics-based simulations with AI and machine learning to address challenges such as data scarcity in drug discovery.
Schrödinger’s news also covers collaborations and co-founded companies. Examples include expanded research agreements with Ajax Therapeutics, Lilly and Otsuka Pharmaceutical, as well as developments from Nimbus, Structure Therapeutics and Copernic Catalysts, all of which use Schrödinger’s platform in different ways. News items have described positive data for molecules such as zasocitinib, co-invented by Schrödinger and Nimbus, and the creation of a new ammonia synthesis catalyst in collaboration with Copernic.
On the corporate side, SDGR news includes quarterly financial results, updated financial guidance, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Pipeline updates for proprietary programs such as SGR-1505, SGR-3515, SGR-5573 and SGR-6016 appear alongside platform and partnership announcements, providing a combined view of software and drug discovery activities.
Investors and researchers can use the SDGR news page to follow earnings releases, platform enhancements, regulatory designations, collaborative milestones and governance disclosures that shape the company’s trajectory.
Schrödinger (Nasdaq: SDGR) will host a conference call and webcast on May 11, 2021, at 8:30 a.m. ET to discuss its first quarter 2021 financial results and provide a business update. The live event can be accessed via the company's investor relations page. Schrödinger utilizes a physics-based software platform for rapid and cost-effective discovery of therapeutics and materials, serving biopharmaceutical companies, academic institutions, and government laboratories globally. Founded in 1990, the company operates with over 450 employees across more than 70 countries.
On April 13, 2021, Schrödinger, Inc. (Nasdaq: SDGR) granted non-statutory stock options for 7,450 shares to three new employees as part of their compensation under the 2021 Inducement Equity Incentive Plan. The options have an exercise price of $75.53 per share and a ten-year term, with a four-year vesting schedule. Schrödinger's physics-based software platform enhances the discovery of therapeutics and materials more efficiently than traditional methods. The company, founded in 1990, has over 450 employees and operates globally across various sectors.
Schrödinger (Nasdaq: SDGR) showcased promising preclinical data for its CDC7 inhibitor program at the AACR Annual Meeting on April 10, 2021. The data revealed that the company's picomolar CDC7 inhibitors effectively inhibited tumor cell growth, both individually and in conjunction with existing cancer treatments. The inhibitors demonstrated strong selectivity by inducing cancer cell apoptosis while sparing healthy cells, particularly in mouse models of acute myeloid leukemia and colorectal cancer. Schrödinger plans to advance these findings into IND-enabling studies in 2022.
Schrödinger (Nasdaq: SDGR) announced that its CEO, Ramy Farid, Ph.D., will participate in the BMO BioPharma Spotlight Series on Technology-Enabled Drug Discovery. The virtual panel is scheduled for Friday, April 16, at 10:00 a.m. ET. An on-demand webcast will be available on Schrödinger's website under the 'News & Events' section and will remain accessible for about seven days. Schrödinger is revolutionizing drug and material discovery through its physics-based software platform, which enhances the speed and cost-effectiveness of developing novel therapeutics.
Schrödinger (Nasdaq: SDGR) announced a webcast to review preclinical data from its CDC7 program at the AACR Annual Meeting on April 12, 2021. The session will also cover overviews of internal programs MALT1 and Wee1, highlighting the computational platform's role in drug discovery. Schrödinger's platform aims to accelerate the discovery of high-quality novel molecules, reducing costs compared to traditional methods. This presentation reflects ongoing efforts in drug development and collaboration with various global entities.
Schrödinger (Nasdaq: SDGR) announced CEO Ramy Farid, Ph.D., will participate in a virtual panel during the Credit Suisse 2021 Healthcare Innovators Series on March 23 at 2:00 p.m. ET. The event focuses on the intersection of drug discovery, drug development, and artificial intelligence. An on-demand webcast will be available on Schrödinger's website and archived for about 7 days. Schrödinger aims to transform therapeutic and material discovery through its physics-based software platform, enhancing efficiency and reducing costs for global organizations.
Schrödinger (Nasdaq: SDGR) announced the presentation of preclinical data from its CDC7 program at the AACR Annual Meeting. Targeting CDC7, a protein kinase critical for DNA replication, presents a novel therapeutic approach in cancer treatment. The presentation, titled "Discovery of novel CDC7 inhibitors that disrupt cell cycle dynamics and show anti-proliferative effects in cancer cells," is scheduled for April 10, 2021. Schrödinger’s software platform aids in accelerating the discovery of innovative therapeutics and materials across various sectors.
Schrödinger, Inc. (Nasdaq: SDGR) reported substantial financial results for Q4 and FY 2020, highlighting a 28% revenue growth in Q4, reaching $33 million, with software revenue surging by 42% to $25 million. The company ended 2020 with $643.2 million in cash and equivalents, enabling strategic investments for future growth. Importantly, Schrödinger entered a collaboration with Bristol Myers Squibb, securing a $55 million upfront payment, with potential milestone payments up to $2.7 billion. Looking ahead, the company expects FY 2021 revenue between $124 million and $142 million.
Schrödinger (Nasdaq: SDGR) announced its participation in the H.C. Wainwright Global Life Sciences Conference, scheduled for March 9-10, 2021. The event will feature a virtual corporate overview, which can be accessed via the 'News & Events' section on Schrödinger’s website. This recorded presentation will be available for approximately 14 days.
Schrödinger is revolutionizing drug and materials discovery through its innovative software platform.
Schrödinger, Inc. (Nasdaq: SDGR) has expanded its collaboration with Google Cloud, replacing a three-year agreement with a new five-year deal. This partnership will provide Schrödinger with hundreds of millions of GPU hours, tripling its previous throughput and enhancing its computational capacity for drug discovery and materials science. Schrödinger's Chief Information Officer emphasized this collaboration strengthens their leadership in molecular modeling and drug development. The goal is to accelerate drug discovery, enabling rapid exploration of chemical space.